← The patent line

Xenon Xe-129 Hyperpolarized

Sold as XENOVIEW · given by inhalation

Five to ten years until it comes off patent
9.4 yr
Until anyone may copy it
Protection runs to 2035-12-29
3
Trials running now
9 registered in total
Phase 2
Furthest stage reached
mid-size trials testing effect
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Polarean Inc
Approval holder
the only company permitted to sell it today
2035-12
Last patent expires
latest patent filed against this product
2027-12
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Interstitial Lung DiseaseIdiopathic Pulmonary FibrosisHypersensitivity Pneumonitis
03

Who is paying for the research

University of Kansas Medical Cente
University or hospital
4
Bastiaan Driehuys
University or hospital
2
University of Virginia
University or hospital
1

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT06122922Phase 22024 · withdrawn
Xenon MRI in Stable Pulmonary Hypertension (

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line